OS Therapies announces positive efficacy and safety data for ovarian cancer therapeutic candidate developed based...

Merck launches single-use reactor designed to accelerate antibody drug conjugate manufacturing

Antibody-Drug Conjugate I-DXd shows clinically meaningful response in patients with extensive-stage small cell lung cancer

AstraZeneca, Daiichi Sankyo’s Dato-DXd fails to significantly improve overall survival in phase III NSCLC

AstraZeneca/Daiichi’s ADC shows better survival for nonsquamous NSCLC patients